Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01758458 · ClinicalTrials.gov registry record · Phase 1
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01758458 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT01758458, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best way to give laboratory treated autologous T cells together with aldesleukin and to see how well it works in treating patients with merkel cell carcinoma that has spread from the primary site (place where it started) to other places in the body. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells to kill tumor cells. Giving cellular adoptive immunotherapy with aldesleukin may be a better treatment for metastatic merkel cell carcinoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- BIOLOGICAL Aldesleukin
- BIOLOGICAL MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- BIOLOGICAL Recombinant Interferon Beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01758458
The ClinicalTrials.gov registry entry for NCT01758458 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01758458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01758458 about?
NCT01758458 is a clinical study titled "Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma". This phase I/II trial studies the side effects and best way to give laboratory treated autologous T cells together with aldesleukin and to see how well it works in treating patients with merkel cell carcinoma that has spread from the primary site (place where it started) to other places in the body....
What is the current status of trial NCT01758458?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01758458?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Aldesleukin (BIOLOGICAL), MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells (BIOLOGICAL), Recombinant Interferon Beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT01758458?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.